Adapalene NEW
| Price | $42 | $66 | $189 |
| Package | 50mg | 100mg | 500mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Adapalene | CAS No.: 106685-40-9 |
| Purity: 99.76% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Adapalene |
| Description | Adapalene (CD271) is a dual RAR and RXR agonist, utilized in the treatment of skin conditions. |
| In vitro | In rhino mice, Adapalene reduces the quantity of comedonal melanin in the epidermis and increases epidermal thickness. Within both normal skin and acne explants, Adapalene decreases the expression of TLR-2 (TLR-2) and IL-10 (IL-10). By upregulating CD1d expression and downregulating the IL-10 expression in keratinocytes, Adapalene modulates the epidermal immune system. This action enhances the interaction between dendritic cells and T lymphocytes, augmenting antimicrobial activity against Propionibacterium acnes. |
| In vivo | In colorectal cancer cell lines CC-531, HT-29, and LOVO, as well as in human foreskin fibroblasts, Adapalene induces caspase-3 activity in tumor cells, inhibits DNA synthesis in a time- and dose-dependent manner, and triggers apoptosis. |
| Storage | keep away from direct sunlight,store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 1 mg/ml, Sonication is recommended. |
| Keywords | RAR/RXR | GOT1 | acne | RARα | Adapalene | Autophagy | Retinoid X receptors | CD 271 | Inhibitor | RARγ | tumor | retinoid | Apoptosis | RAR | CD-271 | Retinoic acid receptors | RARβ | inhibit |
| Inhibitors Related | Stavudine | Sodium 4-phenylbutyrate | L-Ascorbic acid | Hydroxychloroquine | Guanidine hydrochloride | Taurine | Tributyrin | Paeonol | Naringin | Salicylic acid | Gefitinib | Oleic acid |
| Related Compound Libraries | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | NO PAINS Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Orally Active Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Infection Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1g |
VIP1Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2025-01-09 | |
| $0.00/5mg |
VIP1Y
|
Guangzhou Tosun Pharmaceutical Ltd
|
2024-12-30 | |
| $10.00/1KG |
VIP6Y
|
Hebei Weibang Biotechnology Co., Ltd
|
2024-12-04 | |
| $150.00/1kg |
VIP1Y
|
Hebei Zhuanglai Chemical Trading Co Ltd
|
2024-11-25 | |
| $42.00/50mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $1000.00/1kg |
VIP1Y
|
HEBEI SHENGSUAN CHEMICAL INDUSTRY CO.,LTD
|
2024-08-12 | |
| $0.10/1KG |
VIP6Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2024-08-05 | |
| $0.00/25kg |
VIP1Y
|
Hebei Mojin Biotechnology Co.,Ltd
|
2024-07-25 | |
| $5.00/25kg |
Ouhuang Engineering Materials (Hubei) Co., Ltd
|
2024-04-26 | ||
| $8.00/1kg |
VIP2Y
|
Henan Fengda Chemical Co., Ltd
|
2024-04-03 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY